Arcturus Therapeutics Advances H5N1 Vaccine Development for Pandemic Preparedness and Global Health Security

Arcturus Therapeutics Advances Pandemic Preparedness with New Vaccine Candidate

Arcturus Therapeutics Holdings Inc., a San Diego-based biotechnology firm, announces a significant milestone in its mission to combat infectious diseases. The U.S. Food and Drug Administration (FDA) grants a “Study Can Proceed” notification for the company's Investigational New Drug (IND) application concerning ARCT-2304, a self-amplifying messenger RNA (sa-mRNA) vaccine designed to protect against the H5N1 virus, a strain of avian influenza. With this approval, Arcturus is poised to initiate a Phase 1 clinical trial that will enroll approximately 200 healthy adults in the United States. This trial is backed by funding from the Biomedical Advanced Research and Development Authority (BARDA), emphasizing the vaccine's role in bolstering pandemic preparedness.

Joseph Payne, the President and CEO of Arcturus, underscores the significance of this development in the context of future pandemic readiness. The upcoming trial will evaluate the safety, reactogenicity, and immunogenicity of ARCT-2304, which is notable for its ability to produce multiple mRNA copies within host cells post-administration. This innovative mechanism not only enhances the vaccine's efficacy but also allows for lower dosage requirements compared to conventional mRNA vaccines. Additionally, the formulation's stability at refrigerator temperatures addresses critical challenges in cold-chain logistics, making it more feasible for widespread distribution.

Arcturus Therapeutics leverages its advanced LUNAR® lipid-mediated delivery and STARR® mRNA technology, which positions it as a leader in the rapidly evolving field of RNA-based therapeutics and vaccines. The company is also recognized for developing KOSTAIVE®, the world's first approved sa-mRNA COVID-19 vaccine. Its robust pipeline includes mRNA therapeutic candidates targeting conditions such as ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), alongside collaborative vaccine programs aimed at addressing COVID-19 and influenza. Through strategic partnerships, including its joint venture in Japan focusing on mRNA manufacturing, Arcturus Therapeutics is well-equipped to make substantial contributions to public health and infectious disease control.

In addition to its vaccine development efforts, Arcturus Therapeutics remains committed to advancing its RNA therapeutics pipeline. The company's ongoing research and collaboration efforts reflect a broader strategy to utilize RNA technology in addressing a variety of health challenges. As Arcturus moves forward with its clinical trials and partnerships, its innovations may play a crucial role in enhancing global health security against emerging infectious threats.